Medical Human Sexuality

Chapter 43 Medical Human Sexuality





Overview


Sexuality is a fundamental aspect of human self-concept and a complex biopsychosocial process. Physiologic aspects of sexuality are interpreted within the patient’s cultural and social context. Family physicians and primary care providers are well situated to offer patients basic information regarding human sexual health issues and to evaluate and treat most common sexual problems; however, they seldom ask patients about sexual functioning. This chapter describes the basic principles of evaluation of female and male sexual dysfunction and clinical management of common disorders.




Models of Human Sexual Response


Masters and Johnson first described the physiology of “human sexual response cycle” in 1966. Based on the physical components of sexual functioning, they described four phases of the sexual response cycle: excitement, plateau, orgasm, and resolution (Fig. 43-1). Helen Singer Kaplan subsequently described a more subjective, psychologically oriented sexual responsiveness model with three phases: desire, excitement, and orgasm. Recently, however, nonlinear alternative models have been suggested, especially for women’s sexual response (Basson and Schultz, 2007) (Fig. 43-2). In certain settings, men may have similar nonlinear sexual responses. Response phases establish a framework to discuss sexual dysfunction.





Initial Evaluation of Sexual Problems


Many patients would benefit from detection and treatment of sexual problems; however, many clinicians do not ask, and patients may not volunteer the information. In the Global Study of Sexual Attitudes and Behaviors, which surveyed more than 27,000 adults age 40 to 80 in 29 countries, 49% of women and 43% of men reported experiencing at least one sexual problem; fewer than 20% had sought medical assistance for sexual issues (Moreira et al., 2005). Health care providers should proactively and routinely address sexual health.


The sexual health interview may be approached with a screening or abbreviated method, followed by in-depth questioning, if necessary (Nusbaum and Hamilton, 2002) (Box 43-1). The answers on the detailed sexual history then direct the physical examination and appropriate laboratory testing. A physician may open the sexual history questioning with an inclusion technique: “Sexual health is important to overall health, therefore, I ask all my patients about it. I’m going to ask you a few questions on sexual matters now.” The clinician can use normalization or universalization techniques. In normalization the clinician introduces emotionally laden or difficult subjects by implying these experiences are quite prevalent: “Many people have been sexually abused or molested as children. Did you have any experiences like that when you were young?” Universalization phrases questions as if everyone has done everything, making an affirmative answer easier for sensitive questions. For example, patients may be asked “How often do you masturbate?” instead of “Do you masturbate?” The clinician should also reassure the patient about physician-patient confidentiality.



Box 43-1 Questions for a Detailed Sexual History


From Nusbaum MRH, Hamilton CD. The proactive sexual health history. Am Fam Physician 2002;66:1705-1712.HIV, Human immunodeficiency virus; STIs, sexually transmitted infections; IV, intravenous.





















Jack Annon in 1976 proposed the PLISSIT model to approach sexual concerns: Permission, Limited Information, Specific Suggestions, and Intensive Treatment (Box 43-2). The clinician can alternatively use the ALLOW acronym: Ask, Legitimize, Limitations, Open up, and Work together (Hatzichristou et al., 2004), as discussed next.



Ask. Questions regarding sexual functioning should be asked in a matter-of-fact yet sensitive manner. Physicians should avoid terms that make assumptions regarding patients’ sexual behaviors. When inquiring about past or recent sexual encounters, the clinician may inquire “with men, women, or both?” Using the term “partner” instead of “husband” or “boyfriend” or “wife” or “girlfriend” may allow patients to discuss their sexual orientation openly. Slang words should be redefined in medical terminology so that the clinician and patient may communicate clearly.


Legitimize. By acknowledging the clinical relevance of sexual dysfunction, the clinician legitimizes the patient’s sexual problem. Opening questions also can be linked to the patient’s medical problems: “Many people with hypertension and heart disease notice a change in sexual functioning. Have you noticed any change?”


Limitations. The patient’s knowledge may have limitations, and patient education may address the patient’s perceived sexual dysfunction. For example, an older man with longer time between erections may not know the refractory period normally increases with age. Patient education and reassurance may eliminate his perceived “sexual dysfunction.” Physicians should recognize their own limitations and, if necessary, refer a patient to the appropriate specialist for further evaluation and treatment of a sexual dysfunction.


Open up, for further discussion and evaluation. A detailed sexual history may be needed to evaluate fully a patient’s sexual concern (see Box 43-1). If the time constraints limit the current visit, the physician should offer the patient a future follow-up visit.


Work together, to develop a treatment plan. In some cases, simply following the previous four steps may be therapeutic. Many clinical cases can be managed with brief education or limited advice, such as discussing normal physiologic sexual changes with aging or recommending books or products (e.g., water-based lubricant for vaginal dryness). When a referral has been made, scheduled follow-up supports the patient during the process and helps address administrative or adherence issues. Counseling may be extremely important, and the physician should research local resources. The American Association of Sex Educators, Counselors, and Therapists (AASECT) may be contacted for referral information (http://www.aasect.org).



Female Sexual Dysfunction



Key Points








The linear model of sexual functioning classifies female sexual dysfunction as disorders of sexual interest/desire, arousal, orgasm, or pain. The cross-sectional, population-based PRESIDE study (Prevalence and Correlates of Female Sexual Disorders and Determinants of Treatment Seeking) estimated the prevalence of any female sexual problems was 44.2%, with “personal distress” reported by 22.8% of participants (Hatzichristou et al., 2004). Sexual dysfunction associated with personal distress became a disorder defined in the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM-IV-TR).



Hypoactive Sexual Desire Disorder


For women, low sexual drive is the most frequently reported sexual problem. Four in 10 women state they have low sexual drive. The lack of sexual desire may not be distressing for all women, with “distress” prevalence ranging in studies from 23% to 61% (Lindau et al., 2007; Shifren et al., 2008). Hypoactive sexual desire disorder (HSDD) may be general (a general lack of sexual desire), situational (previously present sexual desire is now absent), acquired (beginning after a period of normal sexual function), or lifelong (persistent no or low sexual desire). The cyclic model of sexual functioning postulates that arousal, not desire, may be the initial trigger for a woman’s sexual encounter. Recently, therefore, experts suggest defining HSDD as a recurrent, consistent lack of ability to experience any desire or arousal (Basson et al., 2004). A brief questionnaire can be helpful to screen patients for HSDD (see eTable 43-1 online).


Female sexual desire is a complex interaction among biologic, psychological, social, interpersonal, and environmental components. Ovarian function, especially ovarian androgens, may play an important role. In women age 20 to 49, HSDD is almost threefold more likely in surgical postmenopausal women than premenopausal women. However, no significant difference in HSDD exists between naturally or surgical postmenopausal women over age 50 (Leiblum et al., 2006). Medical illnesses, such as thyroid disease, chronic pain conditions, urinary incontinence, and depression/anxiety, may negatively impact sexual desire. Medications can affect sexual drive, especially selective serotonin reuptake inhibitor (SSRI) antidepressants, antihypertensives, antipsychotics, and narcotics. Fear of pregnancy or sexually transmitted infection and discord or communication difficulty in a couple’s relationship may diminish sexual desire. The clinician must explore all aspects of the biopsychosocial model when evaluating a woman with hypoactive sexual desire.


Evaluation for HSDD includes a thorough history and physical examination to detect any gynecologic, neurologic, cardiovascular, or endocrine disorders. Laboratory testing should include thyroid function, fasting glucose, lipid profile, and liver function. If a hormonal problem is suspected, prolactin, total and free testosterone, sex hormone–binding globulin (SHBG), dihydroepiandrosterone (DHEA), and estrogen levels may be drawn. Androgen levels in premenopausal women should be measured at the peak on days 8 to 10 of a 28-day menstrual cycle.



Treatment


The U.S. Food and Drug Administration (FDA) has not approved any medication specifically for treatment of HSDD. Estrogen therapy improves vaginal dryness but does not affect sexual desire. The manufacturer of oral esterified estrogen and methyltestosterone discontinued distribution in the United States in March 2009. Although the transdermal testosterone patch is approved in Europe (Intrinsa), in 2004 the FDA did not approve it because of concerns regarding relatively low effectiveness, large placebo response, masculinizing side effects, and possible long-term consequences (cardiovascular and breast cancer when given with estrogen). Further Phase III clinical trials are ongoing. A randomized controlled trial (RCT) of sildenafil in postmenopausal women with SSRI-associated sexual dysfunction demonstrated a significant improvement in delayed orgasm and arousal (lubrication), but no improvement in desire (Nurnberg, 2008).


In small studies, bupropion improves HSDD in premenopausal women and women taking SSRIs, but large-study data are lacking (Segraves et al., 2004). Given the lack of allopathic treatment for HSDD, many women turn to complementary and alternative therapies (CAM). DHEA, an adrenocorticosteroid the body converts to testosterone, was found to improve sexual interest, thoughts, and fantasies in women with adrenal insufficiency, but studies are conflicting for women without adrenal insufficiency (Arlt et al., 1999). Limited data exist for Ginkgo biloba, damiana leaf, ginseng, and other proprietary herbal blends that are marketed to improve HSDD (Simon, 2009). For psychological interventions for HSDD, cognitive-behavioral therapy appears most beneficial (Basson et al., 2004).



Female Sexual Arousal Disorder


The DSM-IV-TR defines female sexual arousal disorder as the inability to attain or maintain a genital lubrication-swelling response during sexual activity. The American Foundation for Urologic Disease recommended division of this diagnosis into subjective, genital, and combined subtypes. It also urged recognition of “persistent” sexual arousal disorder characterized by “spontaneous, intrusive, and unwanted genital arousal … unrelieved by one or more orgasms” (Basson et al., 2003).


With the exception of persistent sexual arousal disorder, evaluation should include assessment for hypoactive sexual desire disorder. Neurologic and vascular causes should be considered when adequate genital vasocongestion and swelling do not occur but subjective arousal and lubrication are intact.


Treatment is based on the suspected cause of the sexual arousal disorder. Supplemental water-soluble lubrication may be needed. Off-label use of PDE-5 inhibitors (e.g., sildenafil) may be helpful in restoring the vascular response (Kaplan et al., 1999). The FDA-approved Eros Clitoral Therapy Device uses a silicon cup to apply a vacuum to increase blood flow to the clitoris and surrounding tissue. The device appears effective in women without detectable disease and after radiation treatment for cervical cancer (Munarriz et al., 2003, Schroder et al., 2005), although sample sizes have been small. Herbal supplements and botanical genital massage oil showed some effect in small studies (Ito et al., 2001, Ferguson et al., 2003). Partner issues and situational factors may need to be addressed.



Female Orgasmic Disorder


Orgasmic dysfunction, the inability to reach orgasm when desired, may be primary, with the patient never having experienced orgasm, or secondary, with the dysfunction manifesting after previous satisfactory orgasmic functioning. Some women may believe they have primary inhibited-orgasm disorder because, unlike many men, they do not reach orgasm solely with vaginal intercourse. Portrayals of female orgasm in novels and films are often overstated or misleading. A basic description of physical orgasm (i.e., pleasurable sensation in genital area and contractions of vagina, followed by a feeling of physical and psychological relaxation) may facilitate discussion of orgasm. Many women prefer simultaneous vaginal and clitoral stimulation, oral-genital sex, or clitoral stimulation alone to have an orgasm and do not have an orgasmic disorder.


In both primary and secondary orgasmic dysfunction, it is important to ask about past or current experiences of violence, victimization. and abuse. Social factors also affect a woman’s experience of orgasm. Women taught negative messages regarding sexuality or with strict religious or cultural prohibitions on sexual attraction and thoughts may experience orgasmic difficulty, even if the specified conditions for sexual behavior (e.g., marriage) have been fulfilled. Women who were born later in the 20th century are more likely to experience orgasm than those born earlier, likely reflecting social changes. Secondary inhibited orgasm can be caused by other medical illnesses and contributing contextual factors.


The clinical history in secondary inhibited orgasm should focus on the patient’s perception of this dysfunction: time and circumstances of onset, possible causes, effect on relationship(s), and treatment goals. Physiologic functioning during sexual stimulation, including adequacy of lubrication and ability to sustain states of high arousal, should be explored. Contributing factors such as fatigue, depression, postpartum physical and social changes, preoccupation with other life issues, substance abuse, and other medical illnesses should be considered. Contextual and relationship issues, including lack of tenderness or interest in non-intercourse stimulation by the partner, early ejaculation, problems regarding contraceptive responsibility, lack of privacy, relationship conflicts, and the possibility of abuse, should be discussed. In most cases of orgasmic dysfunction, no specific physical examination or laboratory testing is necessary. As with other sexual dysfunctions, neurologic, gynecologic, or other examination may be suggested by the clinical history.


Treatment of orgasmic dysfunction usually involves increasing knowledge and sexual options for the patient and partner. Masturbation (self-pleasuring) may provide information about sexual responsiveness and preferred stimulations, which can then be transferred to sexual situations with the partner. Partner education regarding clitoral stimulation and adequate pre-intercourse lovemaking (foreplay) can change the focus from intercourse to mutual pleasuring, spontaneity, and sexual satisfaction. Referral for more in-depth therapy is indicated if the evaluation reveals significant relationship dysfunction, past abuse, or other severe medical or psychosocial complications.



Sexual Pain Disorders



Vaginismus


Vaginismus is an involuntary, usually painful, spastic contraction of the pelvic musculature surrounding the outer third of the vagina. It is classified as complete (e.g., precluding intercourse, tampon insertion, or other vaginal penetration), partial (resulting in dyspareunia or difficulty with other forms of vaginal penetration, including speculum examination), or situational (e.g., occurring when intercourse is anticipated). Vaginismus is often idiopathic. Many cases, however, may follow pelvic trauma, such as painful intercourse, sexual assault, rough gynecologic examination, complicated episiotomy, vaginal infections, pelvic inflammatory disease, or pelvic surgery. Childhood or adolescent sexual abuse may also lead to vaginismus during adulthood. Regardless of the cause of vaginismus (traumatic, psychological, or idiopathic), once a pattern of pain and anticipation of pain has been established, it will likely recur unless treatment is provided.


Diagnosis is usually made by history. Patients report pain and difficulty with, or inability to engage in, vaginal intercourse or digital vaginal stimulation; using tampons or vaginal contraceptives; or having a pelvic examination. Patients may demonstrate visible contraction of the pelvic floor musculature with anticipated speculum examination. Physical examination may detect pertinent anatomic abnormalities, such as vaginal septa.


Few studies exist on vaginismus. Uncontrolled reports suggest that sex therapy may be helpful (McGuire and Hawton, 2005). Vaginismus is not under the patient’s conscious control. Therapy must be directed at restoring conscious control under conditions that respect the patient’s autonomy and maintain the patient’s safety from further trauma. If the patient expresses fear or anxiety, pelvic examination may be deferred, and in severe cases, sedation may be necessary. Any physical abnormalities detected on pelvic examination, such as infections, should first be treated. After this, the patient may begin self-treatment with size-graded plastic or silicone vaginal dilators, gradually teaching her vagina to remain relaxed and receive nonpainful, self-controlled penetration (see Web Resources). Specialized physical therapists teach patients to use biofeedback to relax the pelvic floor musculature; this can be more effective than treatment with dilators and is often preferred by patients. Treatment of posttraumatic stress disorder and other sequelae of past trauma may be crucial. Referral to a sex therapist is often helpful.




Dyspareunia


Dyspareunia refers to pain experienced immediately before, during, or after intercourse. Diagnosis of dyspareunia is made by history and physical examination. Useful questions include the onset, duration, and circumstances in which this problem occurred, the location of the pain (e.g., superficial, deep, unilateral, bilateral), and whether it is specific to a particular partner or practice. Physical exam may reveal perineal trauma or vaginal infection, vaginal mucosal atrophy, or other anatomic factors (e.g., vaginal septa, partial vaginismus). Emotional factors may contribute, such as ambivalence or distaste regarding the sexual relationship, as well as the sequelae of childhood abuse. Inadequate lubrication, relationship difficulties, poor sexual technique or a rough or abusive partner can cause dyspareunia.


Treatment of physiologic dyspareunia caused by atrophic vaginitis may require vaginal estrogen. Vaginal infections must be diagnosed and treated. For poor lubrication, supplemental water-based lubrication may be sufficient. Deep dyspareunia is often caused by overvigorous penetration or excess cervical pressure and may respond to brief educational interventions. Many people do not realize that penises and vaginas vary in length, and the vagina may not stretch to accommodate full penile engulfment. Changing position to allow the woman to control the amount of cervical pressure may ameliorate the dyspareunia. Referral for sex therapy for the couple may prove helpful. In some cases, the patient may be able to bring about change in the sexual relationship with sufficient information and assertiveness. If dyspareunia is the result of deliberate carelessness or abuse by the partner, ending the relationship is usually the only reasonable option.



Male Sexual Dysfunction



Key Points






Erectile Dysfunction


Historically, male sexual dysfunction was described as “impotence”; however, the term erectile dysfunction (ED) is now preferred. The National Institutes of Health (NIH) Consensus Development Conference (1992) defined ED as “the inability for a male to achieve an erect penis as part of the overall multifaceted process of male sexual function.” ED becomes “male erectile disorder” defined by the DSM-IV-TR when “marked distress or interpersonal difficulty” accompanies it, and is not better accounted for by another mental health disorder (other than a sexual dysfunction), and not exclusively caused by the direct physiologic effects of a substance (e.g., drug of abuse, medication) or a general medical condition.


Both sympathetic and parasympathetic nerves regulate blood flow into the corpus cavernosum of the penis. Stimulation of the parasympathetic nerves causes release of nitric oxide (NO) from the noradrenergic, noncholinergic nerves and endothelial cells. NO increases the intracellular levels of cyclic guanosine monophosphate (cGMP) in the cavernosal smooth muscle, which relaxes the cavernosal tissues. With the resultant rapid blood flow into the corporal bodies of the penis, the small emissary veins that cross the tunica albuginea are occluded, and blood is trapped inside the corpus cavernosum, leading to an erection. The level of cGMP is also affected by prostaglandins. Phosphodiesterase-5 (PDE-5) is the main cGMP-catalyzing enzyme in human smooth muscle. PDE-5 inhibitors (sildenafil, tadalafil, vardenafil) increase cGMP levels and facilitate and maintain penile erection. The intact functioning of four body systems—vascular, neurologic, endocrine, and usually psychological—is necessary for a man to experience a penile erection.


Erectile dysfunction can occur at any age, but prevalence increases with age; 2% for ages 40 to 49, 6% for 50 to 59, 17% for 60 to 69, and 39% for 70 or older (Inman et al., 2009). Medical conditions associated with peripheral vascular disease, such as diabetes, coronary artery disease, stroke, and hypertension, increase the prevalence of ED. In men younger than 60, smoking, sedentary lifestyle, and being overweight increased the risk for ED (Bacon et al., 2003).


Oct 3, 2016 | Posted by in MANUAL THERAPIST | Comments Off on Medical Human Sexuality

Full access? Get Clinical Tree

Get Clinical Tree app for offline access